Cargando…

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer

Metastatic urothelial carcinoma of the bladder is an aggressive malignancy with poor prognosis, reflecting a lack of effective systemic therapies. The current standard of care includes multiagent platinum-based chemotherapy; however a majority of patients do not respond to treatment and most eventua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aydin, Ahmet Murat, Woldu, Solomon L, Hutchinson, Ryan C, Boegemann, Martin, Bagrodia, Aditya, Lotan, Yair, Margulis, Vitaly, Krabbe, Laura-Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352238/ https://www.ncbi.nlm.nih.gov/pubmed/28331342 http://dx.doi.org/10.2147/OTT.S109453

Ejemplares similares

The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States
por: Fang, Dong, et al.
Publicado: (2020)

Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
por: Küronya, Zsófia, et al.
Publicado: (2022)

Metastatic Melanoma to the Bladder: Case Report and Review of the Literature
por: Patil, Rohit V., et al.
Publicado: (2017)

Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer
por: Kittler, Ralf, et al.
Publicado: (2018)

Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts
por: Tse, Jennifer, et al.
Publicado: (2019)

Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study
por: Chien, Tsu-Ming, et al.
Publicado: (2021)

Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study
por: Passoni, Niccolò M., et al.
Publicado: (2016)

Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma
por: Yeh, Hsin-Chih, et al.
Publicado: (2020)

What is the role of nephrectomy following complete response to checkpoint inhibitors?
por: Woldu, Solomon L., et al.
Publicado: (2018)

Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection
por: Lafin, John T., et al.
Publicado: (2021)

Demographic Factors Associated With Non-Guideline–Based Treatment of Kidney Cancer in the United States
por: Howard, Jeffrey M., et al.
Publicado: (2021)

Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer
por: Hutchinson, Ryan, et al.
Publicado: (2017)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
por: Abbas, Mahmoud, et al.
Publicado: (2023)

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?
por: Klaile, Yvonne, et al.
Publicado: (2016)

Molecular markers in bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma
por: Pradere, Benjamin, et al.
Publicado: (2020)

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer
por: Chen, Lily, et al.
Publicado: (2022)

De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
por: Thakolwiboon, Smathorn, et al.
Publicado: (2019)

Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer
por: Meng, Xiaosong, et al.
Publicado: (2021)

Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

Osteoclast-type giant cell carcinoma of the urinary bladder: An unusual and aggressive variant of urothelial carcinoma
por: Osman, Can, et al.
Publicado: (2018)

Advances in the Management of Patients With Urothelial Carcinomas of the Bladder
por: Shah, Amishi, et al.
Publicado: (2018)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer
por: Clinton, Timothy, et al.
Publicado: (2017)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
por: Youssef, Ramy F., et al.
Publicado: (2011)

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer
por: Zaravinos, Apostolos, et al.
Publicado: (2011)

Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report
por: Rkman, Deni, et al.
Publicado: (2019)

Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab
por: Palacka, Patrik, et al.
Publicado: (2022)

Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
por: Sotelo, M., et al.
Publicado: (2020)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Spotlight on recent advances in cardiovascular biology
por: Kook, Hyun, et al.
Publicado: (2019)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned
por: Gayed, Bishoy A., et al.
Publicado: (2016)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
por: Hoffman-Censits, Jean, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eloo8l7flqi2c94qgl45otqrg8